COMPARATIVE-STUDY OF THE EEG PROFILE OF NEUROLEPTICS SELECTIVE FOR D-1 OR D-2 DOPAMINE-RECEPTORS IN THE RABBIT

被引:4
|
作者
BO, P
SAVOLDI, F
机构
[1] Institute of Neurology C. Mondino, University of Pavia, School of Medicine, I-27100 Pavia
关键词
EEG SPECTRAL ANALYSIS; NEUROLEPTICS; D-1-RECEPTOR AND D-2-RECEPTOR; SCH-23390; RACLOPRIDE;
D O I
10.1016/1043-6618(92)90706-H
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The neuroleptics SCH 23390 and raclopride, which interact selectively with either D-1 or D-2 dopamine receptor, were studied for their effects on electroencephalographic (EEG) activity in the rabbit. Haloperidol (0.3 and 1 mg/kg intravenously, i.v.), which was used for comparison, induced synchronization of the cortical EEG activity. Spectral EEG analysis showed increase of power in the whole frequency range (0.1-38.5 Hz) and in all frequency bands in the cortex, whereas a slight decrease of slow and fast theta activity (3.7-7.2 and 7.2-12.2 Hz) was observed in the hippocampus. Animals appeared sedated and arousal response to somatosensory stimuli was markedly inhibited. SCH 23390 (0.03 and 0.3 mg/kg i.v.) induced periods of cortical synchronization and changes of spectral power qualitatively similar to those accompanying haloperidol administration. The drug slightly reduced the duration of arousal elicited by stimuli. Raclopride (1 and 3 mg/kg i.v.) induced weak EEG changes and little effect on arousal response to stimulation. There was an increase of slow wave activity which was particularly evident in the hippocampus. The data indicate that, although to a lesser degree, the D-1 receptor antagonist SCH 23390 induced EEG effects similar to those of haloperidol, whereas blockade of D-2 receptors by raclopride resulted in different patterns of EEG activity. © 1992.
引用
收藏
页码:67 / 74
页数:8
相关论文
共 50 条
  • [31] EFFECTS OF ADRENALECTOMY ON RESPONSES MEDIATED BY DOPAMINE D-1 AND D-2 RECEPTORS
    FAUNT, JE
    CROCKER, AD
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 162 (02) : 237 - 244
  • [32] GENETIC-STUDY OF DOPAMINE D-1, D-2, AND D-4 RECEPTORS IN SCHIZOPHRENIA
    CAMPION, D
    DAMATO, T
    BASTARD, C
    LAURENT, C
    GUEDJ, F
    JAY, M
    DOLLFUS, S
    THIBAUT, F
    PETIT, M
    GORWOOD, P
    BABRON, MC
    WAKSMAN, G
    MARTINEZ, M
    MALLET, J
    PSYCHIATRY RESEARCH, 1994, 51 (03) : 215 - 230
  • [33] THE ROLE OF D-1 AND D-2 RECEPTORS
    SCHACHTER, M
    BEDARD, P
    DEBONO, AG
    JENNER, P
    MARSDEN, CD
    PRICE, P
    PARKES, JD
    KEENAN, J
    SMITH, B
    ROSENTHALER, J
    HOROWSKI, R
    DOROW, R
    NATURE, 1980, 286 (5769) : 157 - 159
  • [34] ACTIVATION OF D-1 AND D-2 DOPAMINE-RECEPTORS INHIBITS PROTEIN-KINASE-C ACTIVITY IN STRIATAL SYNAPTONEUROSOMES
    GIAMBALVO, CT
    WAGNER, RL
    JOURNAL OF NEUROCHEMISTRY, 1994, 63 (01) : 169 - 176
  • [35] IMMUNOCYTOCHEMICAL LOCALIZATION OF D-1 AND D-2 DOPAMINE-RECEPTORS IN THE BASAL GANGLIA OF THE RAT - LIGHT AND ELECTRON-MICROSCOPY
    YUNG, KKL
    BOLAM, JP
    SMITH, AD
    HERSCH, SM
    CILIAX, BJ
    LEVEY, AI
    NEUROSCIENCE, 1995, 65 (03) : 709 - 730
  • [36] POST-TRAINING MINAPRINE ENHANCES MEMORY STORAGE IN MICE - INVOLVEMENT OF D-1 AND D-2 DOPAMINE-RECEPTORS
    PUGLISIALLEGRA, S
    CABIB, S
    CESTARI, V
    CASTELLANO, C
    PSYCHOPHARMACOLOGY, 1994, 113 (3-4) : 476 - 480
  • [37] D-1 and D-2 dopamine receptors in perinatal and adult basal ganglia
    Boyson, SJ
    Adams, CE
    PEDIATRIC RESEARCH, 1997, 41 (06) : 822 - 831
  • [38] ENDOGENOUS DOPAMINE FUNCTIONALLY ACTIVATES D-1 AND D-2 RECEPTORS IN STRIATUM
    KELLY, E
    NAHORSKI, SR
    JOURNAL OF NEUROCHEMISTRY, 1987, 49 (01) : 115 - 120
  • [39] Characteristics of tetrahydroprotoberberines on dopamine D-1 and D-2 receptors in calf striatum
    Guo, X
    Wang, LM
    Liu, J
    Jin, GZ
    ACTA PHARMACOLOGICA SINICA, 1997, 18 (03): : 225 - 230
  • [40] DOPAMINE AGONISTS USED IN THE TREATMENT OF PARKINSONS-DISEASE AND THEIR SELECTIVITY FOR THE D-1 D-2, AND D-3 DOPAMINE-RECEPTORS IN HUMAN STRIATUM
    DEKEYSER, J
    DEBACKER, JP
    WILCZAK, N
    HERROELEN, L
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1995, 19 (07): : 1147 - 1154